Kite Pharma
Signal active
Investment Firm
Overview
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.
Highlights
Founded
2009
Industry
Biotechnology
Employees
1001-5000
Investment
12
Lead Investment
2
Exits
4
Stages
Early Stage Venture, Late Stage Venture
Investor Type
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
Kite Pharma, established in 2009 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across Biotechnology, Health Care, Therapeutics, Information Technology, Software, Financial Services, Venture Capital, Finance, CleanTech, Pharmaceutical. The organization boasts a portfolio of 12 investments, with an average round size of $81.5M and 4 successful exits. Their recent investments include Cell Design Labs, OUP (Osage University Partners), Kleiner Perkins, Mission Bay Capital, Two River. The highest investment round they participated in was $64.6B. Among their most notable exits are Cell Design Labs and OUP (Osage University Partners). Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
Investment portfolio
Kite Pharma has made 12 investments. Their most recent investment was on Nov 15, 2023, when Arcellx raised $200.0M.
Kite Pharma has made 3 diversity investments. Their most recent diversity investment was on Feb 24, 2021, when Orna Therapeutics raised $80.0M.
investments
12
Diversity investments
3
Lead investments
2
Number of exits
4
Investments
12
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Jul 27, 2022 | - | - | 126.6M |
| Dec 09, 2022 | Arcellx | Biotechnology | 100.0M |
| May 16, 2023 | Ensoma | Biotechnology | 50.0M |
| Nov 15, 2023 | Arcellx | Biotechnology | 200.0M |
Exits
4
Funding Timeline
Funding rounds
12
Investors
5
Funds
0
Funding Rounds
12
Kite Pharma has raised 12 rounds. Their latest funding was raised on Nov 15, 2023 from a Post-IPO Equity - Arcellx round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Jul 27, 2022 | Post-IPO Equity - AlloVir | - | 126.6M | - |
| Dec 09, 2022 | Post-IPO Equity - Arcellx | - | 100.0M | - |
| May 16, 2023 | Series B - Ensoma | - | 50.0M | - |
| Nov 15, 2023 | Post-IPO Equity - Arcellx | - | 200.0M | - |
Investors
8
Kite Pharma is funded by 8 investor(s). Alta Partners and Bellco Capital Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
Bellco Capital | No | Series A - Kite Pharma | 20.0M |
Alta Partners | Yes | Series A - Kite Pharma | 20.0M |
| - | No | Debt Financing - Kite Pharma | 50.0M |
| - | No | Post-IPO Equity - Kite Pharma | 250.1M |
Alta PartnersFund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.